- Home
- STEW vs NVCR Comparison
STEW vs NVCR Comparison
Compare STEW & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | NVCR |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | STEW | NVCR |
|---|---|---|
| Price | $18.03 | $13.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 94.8K | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $10.50 |
| Revenue Next Year | N/A | $4.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $15.00 | $9.82 |
| 52 Week High | $18.67 | $21.55 |
Technical Indicators
Market Signals| Indicator | STEW | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 58.94 |
| Support Level | $17.64 | $12.66 |
| Resistance Level | $18.34 | $14.13 |
| Average True Range (ATR) | 0.23 | 1.06 |
| MACD | -0.01 | 0.39 |
| Stochastic Oscillator | 37.33 | 70.04 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.